title: [Effect of intravaginal administration of cisplatin (CDDP) suppositories to uterine cervical cancer--blood and tissue concentrations and the therapeutic effects].
abstract: Four patients with cervical cancer (squamous cell carcinoma: two cases of stage Ib, one of stage IIa, adenocarcinoma: one of stage Ib), were treated preoperatively by intravaginal administration of CDDP (20 mg) suppositories with pessary 7 times every other day. The uptake, distribution and antitumor effect of CDDP were investigated. Results were as follows. 1) Serum total platinum (Pt) concentration varied between individual patients. Cmax profile (0.17-0.57 micrograms/ml) of Pt was observed at 12 hours after the total dose of 140 mg administration in all patients. 2) The tissue Pt concentration showed high values in the cervix (average 55.4 micrograms/g), followed by the vagina (13.13), endometrium (3.17), uterine wall (0.64), ovary (0.57), lymph node group: parametrial (1.14), obturator (0.34), inguinal (0.28), external iliac (0.51), internal iliac (0.42) and common iliac (0.54). Para-aortic node value was too low to detect. 3) Colposcopic findings were disappearance of bleeding and reduction of tumor outgrowth. Microscopic findings were degeneration and necrosis of cancer nest from the surface to about 2 mm depth of the cervix. In conclusion, it may be necessary to improve CDDP penetration from the tumor surface for effective local chemotherapy.
authors: Dept. of Obstetrics and Gynecology, Kure National Hospital, Chugoku District Cancer Center.
authors: T
authors: T
authors: Fujii
authors: H
authors: H
authors: Naito
authors: H
authors: H
authors: Kioka
authors: Y
authors: Y
authors: Tanioka
authors: J
authors: J
authors: Murakami
authors: M
authors: M
authors: Sanada
authors: H
authors: H
authors: Tanimoto
authors: H
authors: H
authors: Nakagawa
authors: T
authors: T
authors: Tanaka
authors: J
authors: J
authors: Furui
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000282:Administration, Intravaginal; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism; D002584:Cervix Uteri / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D004717:Endometrium / Q000378:metabolism; D005260:Female; D006801:Humans; D010053:Ovary / Q000378:metabolism; D013488:Suppositories; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014599:Uterus / Q000378:metabolism
chemical_list: D013488:Suppositories; D002945:Cisplatin